 | | Vol. 4.48 – 18 December, 2020 |
| |
|
|
| Levels and functional effects of SUMOylation, along with response to S-adenosylmethionine and/or short-hairpin RNAs against UBE2I, were evaluated in vitro, in vivo and/or in patients with polycystic liver diseases. SUMOylated proteins were determined by immunoprecipitation and proteomic analyses by mass spectrometry.
[Journal of Hepatology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers discovered that gefitinib could sequentially activate macroautophagy/autophagy and apoptosis in hepatocytes. The inhibition of autophagy alleviated gefitinib-induced apoptosis, whereas the suppression of apoptosis failed to lessen gefitinib-induced autophagy.
[Autophagy] |
|
|
|
| Scientists showed that PKCδ is a secretory protein that regulated cell growth of liver cancer. Full-length PKCδ was secreted to the extracellular space in living liver cancer cells under normal cell culture conditions and in xenograft mouse models.
[Cancer Research] |
|
|
|
| The expression of endoplasmic reticulum (ER) stress and autophagy markers was evaluated in vivo and in vitro. Compared to the normal mice, the serum lipid level and adipose tissue were increased in obese mice, while salubrinal attenuated obesity by blocking lipid disorder.
[Cell Death & Disease] |
|
|
|
| The authors report that activating transcription factor 3 (ATF3) was over-expressed in mice and human fibrotic livers, in activated hepatic stellate cells and injured hepatocytes.
[Cell Death & Disease] |
|
|
|
| Characterization showed both organoid types were highly similar, though some differences in size and gene expression were observed. Both extrahepatic cholangiocyte organoids and ICO have cholangiocyte fate differentiation capacity.
[Scientific Reports] |
|
|
|
| Investigators characterized the aberrant upregulation of CDK11B and downregulation SAM pointed domain-containing ETS transcription factor (SPDEF) in hepatocellular carcinoma tissues and cells.
[Cancer Gene Therapy] |
|
|
|
| The authors found impaired Kupffer cell bacterial clearance and systemic bacterial dissemination in mice with liver injury. Increased PD-1 and PD-L1 expression was detected in Kupffer cells and lymphocyte subsets, respectively, during resolution of injury.
[European Journal of Clinical Investigation] |
|
|
|
| Scientists present a human PSC-derived model of hepatic steatosis, which overcomes inherent challenges of current models, and provides insights into the metabolic rewiring associated with steatosis.
[iScience] |
|
|
|
| Investigators showed a clinically relevant thermal ablation modality that generated tumor-specific hyperthermia, termed molecularly targeted photothermal ablation, that was based upon the excellent localization of indocyanine green to hepatocellular carcinoma.
[Communications Biology] |
|
|
|
|
| Biomimetic human liver imcrophysiology systems have evolved from simpler 2D cell models, spheroids and organoids to address the increasing need to understand patient-specific mechanisms of complex and rare diseases, the response to therapeutic treatments, and the absorption, distribution, metabolism, excretion and toxicity of potential therapeutics.
[Nature Reviews Gastroenterology & Hepatology] |
|
|
|
| The authors review the gut microbiota, liver immunology, and the interaction between the gut and liver.
[Cellular & Molecular Immunology] |
|
|
|
| CDK13 is amplified in hepatocellular carcinoma. Consequently, selective CDK12/13 inhibitors constitute powerful research tools as well as promising anti-cancer therapeutics, either alone or in combination therapy.
[Future Medicinal Chemistry] |
|
|
|
|
| As Maryland deals with a record number of people hospitalized due to COVID-19, state officials also are working to contain an outbreak of hepatitis A, a highly contagious infectious disease for which a vaccine exists.
[The Baltimore Sun] |
|
|
|
| Albireo Pharma, Inc. announced the initiation of its global Phase III pivotal trial, Alagille Syndrome looking at Safety and Efficacy in a Randomized controlled Trial (ASSERT), which will evaluate odevixibat in patients with Alagille syndrome.
[Albireo Pharma, Inc.] |
|
|
|
| Metacrine, Inc. has reported preliminary results from its Phase I trial of MET642, a farnesoid X receptor (FXR) agonist being developed for the treatment of non-alcoholic steatohepatitis and inflammatory bowel disease. Findings show that treatment with MET642 was safe and generally well-tolerated and demonstrated a sustained pharmacokinetic profile and robust FXR target engagement after 14 days of daily oral dosing in healthy volunteers.
[Metacrine, Inc.] |
|
|
|
|
| January 13 – 14, 2021
Virtual |
|
|
|
|
|
| | Pfizer – Cambridge, Massachusetts, United States |
|
|
|
| | University of Oslo – Oslo, Norway |
|
|
|
| | University of Cincinnati – Cincinnati, Ohio, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | Stanford University – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
